Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

  • Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMECwNlg4KM7:TR?= MWfTRW5ITVJ?
LC-2-ad MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMECwN|E4KM7:TR?= MlPhV2FPT0WU
RL95-2 NUfLZYNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMECwOlY5KM7:TR?= M2\aXXNCVkeHUh?=
MZ1-PC M3vnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DIVWlEPTB;MD6wNFA4OjlizszN NUTCU3Y4W0GQR1XS
TE-8 NVrIOHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrrTWM2OD1yLkCwNVE4KM7:TR?= NHrycXdUSU6JRWK=
SW954 NV[5UGM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7CbIxKSzVyPUCuNFAyOTlizszN MVzTRW5ITVJ?
TE-11 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\JUVh2UUN3ME2wMlAxOTJ|IN88US=> NFnvRlZUSU6JRWK=
PSN1 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P2dGlEPTB;MD6wNFE{KM7:TR?= MXrTRW5ITVJ?
MOLT-4 NXTafnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHTUZRKSzVyPUCuNFAyPDlizszN M4XxenNCVkeHUh?=
697 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\FVoFKSzVyPUCuNFAyPSEQvF2= NHvEdWRUSU6JRWK=
ETK-1 NUXW[4xrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlexTWM2OD1yLkCwNVUzKM7:TR?= NX3I[2JQW0GQR1XS
TE-10 M4XJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMECxOVQh|ryP M124XHNCVkeHUh?=
HUTU-80 M4HieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD4ZW5tUUN3ME2wMlAxOTZ6IN88US=> M2mzPXNCVkeHUh?=
NTERA-S-cl-D1 M3\VdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMECyNFkh|ryP MmrrV2FPT0WU
MFH-ino MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnndZRRUUN3ME2wMlAxOjZ6IN88US=> MofSV2FPT0WU
IA-LM MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPLSoRrUUN3ME2wMlAxOjhizszN MXvTRW5ITVJ?
MC116 NXvnT21VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO0R2tGUUN3ME2wMlAxOjh7IN88US=> MkHhV2FPT0WU
RKO MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\1TWM2OD1yLkCwNlk5KM7:TR?= M4\uR3NCVkeHUh?=
MRK-nu-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f0TGlEPTB;MD6wNFI6QSEQvF2= M1LOTXNCVkeHUh?=
VA-ES-BJ NGfDRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULRVZR3UUN3ME2wMlAxOyEQvF2= NULaW3pHW0GQR1XS
KALS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:5S4J4UUN3ME2wMlAxOzB6IN88US=> M1uzXnNCVkeHUh?=
BB30-HNC Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\id5JKSzVyPUCuNFA{OTRizszN MYPTRW5ITVJ?
ACN NXnkTnhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMECzNVYh|ryP M3LuXHNCVkeHUh?=
TE-9 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq3[5FKSzVyPUCuNFA{OjZizszN M1LQ[XNCVkeHUh?=
SIG-M5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe4UVhKSzVyPUCuNFA{OjdizszN NGT2VINUSU6JRWK=
no-10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\nTWM2OD1yLkCwN|YzKM7:TR?= MVHTRW5ITVJ?
EW-1 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnY[5BKSzVyPUCuNFA{PzFizszN NFHYR29USU6JRWK=
SK-LMS-1 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHJbmpKSzVyPUCuNFA1ODFizszN MlfrV2FPT0WU
GT3TKB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfF[W9bUUN3ME2wMlAxPDN2IN88US=> MWHTRW5ITVJ?
ES4 M37CVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X2[2lEPTB;MD6wNFQ1QSEQvF2= NHnJdnNUSU6JRWK=
IMR-5 NHzMd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPSV2pOUUN3ME2wMlAxPDVizszN NXr5b2NKW0GQR1XS
NCI-H1648 NGPXR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEC0Olkh|ryP NXfS[5hUW0GQR1XS
MV-4-11 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\CdnRKSzVyPUCuNFA1PzVizszN NF;ZOpZUSU6JRWK=
SK-UT-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7kRY1LUUN3ME2wMlAxPDhizszN NEHXOpBUSU6JRWK=
NB13 NWK4ZYQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPROZl3UUN3ME2wMlAxPDlzIN88US=> M2X6NXNCVkeHUh?=
DJM-1 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXDNZZWUUN3ME2wMlAxPTNizszN M2m5dHNCVkeHUh?=
ES8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnNW2VWUUN3ME2wMlAxPTN6IN88US=> NWGzfZZKW0GQR1XS
TE-6 NH3mW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33uNGlEPTB;MD6wNFU4KM7:TR?= M3zJfXNCVkeHUh?=
KS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjLWFN4UUN3ME2wMlAxPTh{IN88US=> NGnrWIlUSU6JRWK=
TE-1 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWeyNGxLUUN3ME2wMlAxPjB4IN88US=> MmG3V2FPT0WU
ATN-1 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEC2NFkh|ryP MWfTRW5ITVJ?
A4-Fuk MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXiTWM2OD1yLkCwOlEyKM7:TR?= MmX5V2FPT0WU
ALL-PO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEC2N{DPxE1? M4XPfHNCVkeHUh?=
BE-13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDWTWM2OD1yLkCwOlM3KM7:TR?= NI\wVnpUSU6JRWK=
KM12 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEC2N|ch|ryP NX3pVJF6W0GQR1XS
NOS-1 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7VTWM2OD1yLkCwOlUh|ryP MoDnV2FPT0WU
SW962 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjHb4pKSzVyPUCuNFA3PjJizszN NGTTOpJUSU6JRWK=
OCUB-M M3mx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf6fIpUUUN3ME2wMlAxPjZ{IN88US=> MmXGV2FPT0WU
NCI-H510A NY\XT3A4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7qTWM2OD1yLkCwOlY2KM7:TR?= NIDEWJlUSU6JRWK=
EW-16 M2m3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r1UGlEPTB;MD6wNFY6PCEQvF2= M2rwWnNCVkeHUh?=
KGN NFPpR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HYc2lEPTB;MD6wNFcyOiEQvF2= MX3TRW5ITVJ?
LS-411N M4q0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOxSpVKSzVyPUCuNFA4OTdizszN NF;FWWJUSU6JRWK=
Becker M{LCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvsWXNKSzVyPUCuNFA4OiEQvF2= M1;3dHNCVkeHUh?=
HC-1 MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHFTWM2OD1yLkCwO|IyKM7:TR?= NIfxdINUSU6JRWK=
CESS NUfXcZNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEC3N|ch|ryP MVTTRW5ITVJ?
KURAMOCHI NY[yNphWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrnTWM2OD1yLkCwO|Q5KM7:TR?= M{TESHNCVkeHUh?=
TGBC24TKB MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMEC3OVIh|ryP MVfTRW5ITVJ?
SW982 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65cZdKSzVyPUCuNFA4PjZizszN MVPTRW5ITVJ?
HCE-4 M3TQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEC3Olch|ryP M{jhWHNCVkeHUh?=
LOUCY NXL2blYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7JTWM2OD1yLkCwO|c2KM7:TR?= MUXTRW5ITVJ?
8-MG-BA MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP6TWM2OD1yLkCwO|k3KM7:TR?= NFv0S3ZUSU6JRWK=
HT-144 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzER21KSzVyPUCuNFA5KM7:TR?= Mn7zV2FPT0WU
LXF-289 NHrxN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPYO4NiUUN3ME2wMlAxQDF6IN88US=> NUXodm44W0GQR1XS
RS4-11 NUXsdnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fzNmlEPTB;MD6wNFg{PiEQvF2= MkTEV2FPT0WU
DEL NEHZNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjZZpJJUUN3ME2wMlAxQDR3IN88US=> NVu2NGp7W0GQR1XS
OCI-AML2 M3LNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OxbmlEPTB;MD6wNFg2OiEQvF2= NFXzU2RUSU6JRWK=
CCRF-CEM MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULUTGdUUUN3ME2wMlAxQDdzIN88US=> Mn7lV2FPT0WU
A388 NV7JSJdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG5TWM2OD1yLkCwPFc1KM7:TR?= Mny5V2FPT0WU
KNS-42 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLDb3RKSzVyPUCuNFA5QTFizszN M4\PWXNCVkeHUh?=
OVCAR-4 NIX0c3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi3TWM2OD1yLkCwPVA1KM7:TR?= NIHVO2xUSU6JRWK=
NCI-H1355 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jwNmlEPTB;MD6wNFkyPCEQvF2= NV\LR29GW0GQR1XS
BL-70 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEC5N{DPxE1? NHfUTXFUSU6JRWK=
BL-41 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ZTWM2OD1yLkCwPVM1KM7:TR?= M17uOHNCVkeHUh?=
A101D NH7pd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULUUnlsUUN3ME2wMlAxQTZizszN M4LQe3NCVkeHUh?=
HL-60 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy5dI5qUUN3ME2wMlAxQTZ4IN88US=> NHTaU2FUSU6JRWK=
COR-L279 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEC5PVkh|ryP NX7tT3piW0GQR1XS
NCI-SNU-16 NHLhZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L0ZWlEPTB;MD6wNVAxQCEQvF2= NXvJOIZkW0GQR1XS
Calu-6 NYLiSXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H3RWlEPTB;MD6wNVAyOiEQvF2= M4XFVHNCVkeHUh?=
SR Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KySmlEPTB;MD6wNVAzPiEQvF2= NVjQS|U4W0GQR1XS
QIMR-WIL M3L1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjCfGdKSzVyPUCuNFExOzNizszN M1PDR3NCVkeHUh?=
LB647-SCLC MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULVUFR5UUN3ME2wMlAyODVzIN88US=> M1\wSXNCVkeHUh?=
RPMI-8226 NFvUc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEGxNFIh|ryP MnS3V2FPT0WU
SK-PN-DW M3HaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULQb2VMUUN3ME2wMlAyOTF{IN88US=> NGjTTldUSU6JRWK=
SF268 M1Hm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEGxOVEh|ryP NI\TfmhUSU6JRWK=
HD-MY-Z NHi0PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\OV2lEPTB;MD6wNVE3OyEQvF2= MlznV2FPT0WU
DOHH-2 M3fYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[4O2lSUUN3ME2wMlAyOjB|IN88US=> MXHTRW5ITVJ?
SCC-3 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LhNWlEPTB;MD6wNVIxPCEQvF2= NHLWbIVUSU6JRWK=
ST486 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPQTWM2OD1yLkCxNlA1KM7:TR?= NXnpeXhZW0GQR1XS
NALM-6 M131VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEGyNVQh|ryP M4nnNnNCVkeHUh?=
NCI-H1436 NGewOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHoTWM2OD1yLkCxNlMyKM7:TR?= NYHnV|JsW0GQR1XS
KE-37 NHHtRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLuTWM2OD1yLkCxNlM1KM7:TR?= NI\ybIRUSU6JRWK=
RPMI-8402 NEjEUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEGyOVYh|ryP NH;jdJRUSU6JRWK=
RXF393 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHny[FVKSzVyPUCuNFEzPTdizszN M3y5PHNCVkeHUh?=
KARPAS-45 NH[3OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;DTWM2OD1yLkCxNlch|ryP NF3wRopUSU6JRWK=
HOP-62 NVH2cHNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjpTWM2OD1yLkCxNlc3KM7:TR?= NInTOmxUSU6JRWK=
ES1 NVXOSVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDqO5dKSzVyPUCuNFEzQDhizszN NG\Zb4pUSU6JRWK=
L-363 M{PIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjFe3lKSzVyPUCuNFE{PTFizszN M4XyfXNCVkeHUh?=
GI-1 NWfCSHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf5TZVyUUN3ME2wMlAyOzd|IN88US=> NXKx[lNIW0GQR1XS
CTV-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;VZ2lEPTB;MD6wNVQ4QCEQvF2= NGm5WItUSU6JRWK=
TE-5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMEG0PVYh|ryP NXTWPFh6W0GQR1XS
SNU-C2B MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEG0PVYh|ryP MmXTV2FPT0WU
K-562 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjhO5pUUUN3ME2wMlAyPTF4IN88US=> MlXHV2FPT0WU
SNB75 M4iyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXlTWM2OD1yLkCxOVQh|ryP M1fKbHNCVkeHUh?=
MOLT-13 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULPcmZ[UUN3ME2wMlAyPjN5IN88US=> MUHTRW5ITVJ?
LS-123 NILafFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HjcGlEPTB;MD6wNVY3PCEQvF2= NH:5c3JUSU6JRWK=
NCI-SNU-5 NXHXe2RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\kbG1KUUN3ME2wMlAyPzBzIN88US=> MXTTRW5ITVJ?
Daudi MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHwTWM2OD1yLkCxO|A5KM7:TR?= M3H4U3NCVkeHUh?=
A253 NVS2UmxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rCOGlEPTB;MD6wNVc{QCEQvF2= NEDzdJVUSU6JRWK=
TGBC1TKB M2PVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEG3OVIh|ryP MYnTRW5ITVJ?
SJSA-1 NVfpO4ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\hVFRKSzVyPUCuNFE4PjdizszN NWTRfmlMW0GQR1XS
NCCIT NHftWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEG3Olkh|ryP MYLTRW5ITVJ?
NCI-H69 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G0V2lEPTB;MD6wNVc4QCEQvF2= NYLmV5U1W0GQR1XS
SH-4 NHOwV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDFTWM2OD1yLkCxPFk2KM7:TR?= MUHTRW5ITVJ?
HCC1187 NWHJT3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEG5NlQh|ryP NVvsfVVzW0GQR1XS
HCC1599 NXi3dZllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvYOnpKSzVyPUCuNFIxOiEQvF2= MX\TRW5ITVJ?
ONS-76 NV7mPJNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ywe2lEPTB;MD6wNlA{PiEQvF2= NVz6b2ZuW0GQR1XS
KU812 M2nQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHiyTZVKSzVyPUCuNFIxOzlizszN NHfMdJJUSU6JRWK=
ML-2 NGTlfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nlSmlEPTB;MD6wNlA1PyEQvF2= MUHTRW5ITVJ?
HCE-T Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEKwPVIh|ryP NWHKXm94W0GQR1XS
NCI-H446 NIjDd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrVSHZKSzVyPUCuNFIyOTJizszN NIroU4VUSU6JRWK=
RPMI-6666 NFjTWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PxSWlEPTB;MD6wNlE1QSEQvF2= NY\lTYQ{W0GQR1XS
MOLT-16 NGq1SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\TTWM2OD1yLkCyNVU{KM7:TR?= NYDRWYFoW0GQR1XS
JiyoyeP-2003 NHfFXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7kUolKSzVyPUCuNFIyPzZizszN NFOz[I9USU6JRWK=
MHH-PREB-1 M2G2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELoeHZKSzVyPUCuNFIyQTFizszN MnXpV2FPT0WU
MC-CAR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMEKzNlYh|ryP NIfLWFZUSU6JRWK=
BC-3 NYSydnJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEKzOFQh|ryP MV\TRW5ITVJ?
KINGS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Hk[GlEPTB;MD6wNlM2PSEQvF2= NHXIVllUSU6JRWK=
PF-382 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXRTXlKSzVyPUCuNFI{PzhizszN MXfTRW5ITVJ?
J-RT3-T3-5 M3;5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XWPWlEPTB;MD6wNlM5OyEQvF2= NETSNo1USU6JRWK=
SF539 MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPrWIZKSzVyPUCuNFI1ODFizszN NWnnbWxqW0GQR1XS
LB831-BLC NUfzOYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX36WVYxUUN3ME2wMlAzPDh3IN88US=> NIG3S5RUSU6JRWK=
DMS-114 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\kPFFZUUN3ME2wMlAzPTB{IN88US=> NYjkdZZSW0GQR1XS
LB1047-RCC MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEK1NUDPxE1? MXLTRW5ITVJ?
LB771-HNC MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7XRmFKSzVyPUCuNFI2OzRizszN M3q2NnNCVkeHUh?=
BB65-RCC NGO0[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;yS2pOUUN3ME2wMlAzPTN2IN88US=> NXPlRWJ2W0GQR1XS
BV-173 NHK2d3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;SS2lEPTB;MD6wNlU2PCEQvF2= M4fVTnNCVkeHUh?=
ARH-77 M3i0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rVd2lEPTB;MD6wNlYxOSEQvF2= MoDsV2FPT0WU
IST-MEL1 NVj4O4FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEK2NlMh|ryP MWDTRW5ITVJ?
NB1 NXHEcXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M374fWlEPTB;MD6wNlY5PyEQvF2= MVHTRW5ITVJ?
EoL-1-cell NUe1R|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMEK2PFgh|ryP NF21OFNUSU6JRWK=
KY821 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\od2lEPTB;MD6wNlY6PyEQvF2= NVy5W41NW0GQR1XS
CMK NF\1UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOxTWM2OD1yLkCyO|M1KM7:TR?= NGjVbpNUSU6JRWK=
NCI-H2126 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn3OnlKSzVyPUCuNFI4PjhizszN NVSyNXRUW0GQR1XS
NCI-H526 NYL2cmE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjwPG97UUN3ME2wMlAzQDlzIN88US=> MlfYV2FPT0WU
COLO-684 NIPqdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTOW2ZKSzVyPUCuNFI6ODhizszN NX3JWJZ3W0GQR1XS
NCI-H747 NFvLWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG1TWM2OD1yLkCyPVM{KM7:TR?= M{T2THNCVkeHUh?=
JAR M16zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:5T|ZMUUN3ME2wMlAzQTR4IN88US=> NHPOTHpUSU6JRWK=
MEG-01 NV7EbXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zBN2lEPTB;MD6wNlk4QCEQvF2= NI\yfllUSU6JRWK=
MONO-MAC-6 NFLt[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX0THB2UUN3ME2wMlA{ODJ|IN88US=> Ml:xV2FPT0WU
IST-SL1 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHnTWM2OD1yLkCzNFQzKM7:TR?= NFnnbJNUSU6JRWK=
CPC-N M4fEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHZWJBKSzVyPUCuNFMxPzlizszN NI\3[2dUSU6JRWK=
NCI-H1963 NH7vcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXK[GJKSzVyPUCuNFMyOzFizszN MoHBV2FPT0WU
K052 NXPocY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WzNmlEPTB;MD6wN|I1PyEQvF2= MmD0V2FPT0WU
KM-H2 NXTGb3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi0dotKSzVyPUCuNFM{ODdizszN MUXTRW5ITVJ?
TE-12 NVqxbJU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPvTWM2OD1yLkCzN|A6KM7:TR?= MmfrV2FPT0WU
TK10 M4XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYraTYU{UUN3ME2wMlA{OzV4IN88US=> M1:0[3NCVkeHUh?=
NMC-G1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEO0OVIh|ryP MknTV2FPT0WU
no-11 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET4T3NKSzVyPUCuNFM1PzhizszN M4\VXXNCVkeHUh?=
NCI-H524 NFLsW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEO1Nlkh|ryP MkXSV2FPT0WU
MHH-CALL-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\oTWM2OD1yLkCzOVYzKM7:TR?= M2X6NnNCVkeHUh?=
GB-1 NIHnco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[xZmlEPTB;MD6wN|Yh|ryP NULLNXBCW0GQR1XS
OPM-2 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnw[XFKSzVyPUCuNFM3PzNizszN M{Tr[HNCVkeHUh?=
RH-1 NUnPc25GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEO4NVkh|ryP NUW3eIRUW0GQR1XS
NCI-H64 NGHibnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[xb2lEPTB;MD6wN|g2PyEQvF2= MmL2V2FPT0WU
EVSA-T Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XXeGlEPTB;MD6wN|kzOyEQvF2= MkfVV2FPT0WU
KARPAS-299 NFuxTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7nU5ZKSzVyPUCuNFM6QCEQvF2= MXXTRW5ITVJ?
MZ7-mel M2r4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDLeI9uUUN3ME2wMlA1ODRizszN NIGyR49USU6JRWK=
LB373-MEL-D MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LwOmlEPTB;MD6wOFExPSEQvF2= NVP2W2Y4W0GQR1XS
HEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu1TWM2OD1yLkC0NVQh|ryP NUTUe4poW0GQR1XS
SW872 NYfG[Xl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle3TWM2OD1yLkC0NlEh|ryP M3v3bXNCVkeHUh?=
DU-4475 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[3V2k6UUN3ME2wMlA1OjR2IN88US=> NGjMOldUSU6JRWK=
IST-SL2 M1W1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn2R4JKSzVyPUCuNFQzPzVizszN MmixV2FPT0WU
NCI-H82 NGntUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6XG5KSzVyPUCuNFQ{ODdizszN NFjiRW5USU6JRWK=
LC4-1 NVzpVGtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nlU2lEPTB;MD6wOFM2OSEQvF2= MVPTRW5ITVJ?
HDLM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXwV2JKSzVyPUCuNFQ{QTJizszN NXjRNJl4W0GQR1XS
MMAC-SF NYfpUnBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnjS3hKUUN3ME2wMlA1PTN2IN88US=> MmnQV2FPT0WU
L-540 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfCWnNKSzVyPUCuNFQ3OzlizszN MoryV2FPT0WU
MZ2-MEL NUWwfHVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljwTWM2OD1yLkC0O|QzKM7:TR?= MXHTRW5ITVJ?
LU-134-A NGHLcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnPTWM2OD1yLkC0O|c{KM7:TR?= MXrTRW5ITVJ?
UACC-257 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMES4OFkh|ryP NVLqUll1W0GQR1XS
NCI-H1581 NH72bG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Gz[mlEPTB;MD6wOFk2OyEQvF2= MUfTRW5ITVJ?
NB17 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTBSHRmUUN3ME2wMlA1QTd7IN88US=> MWXTRW5ITVJ?
SBC-1 M4DJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTtVY5GUUN3ME2wMlA2ODR{IN88US=> M1fYV3NCVkeHUh?=
TALL-1 NV;JSVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL3XoxuUUN3ME2wMlA2ODR3IN88US=> NFnxOmRUSU6JRWK=
NCI-H1304 M3rlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKxS4lKSzVyPUCuNFUzODhizszN MnjGV2FPT0WU
NEC8 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF2zSZVKSzVyPUCuNFUzQDZizszN NEO0dXVUSU6JRWK=
CAL-148 MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEW0N|kh|ryP MWnTRW5ITVJ?
CGTH-W-1 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPkTFhKSzVyPUCuNFU1PDlizszN Mo\mV2FPT0WU
NCI-H889 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrMbZRKSzVyPUCuNFU2QTJizszN NGTBbZBUSU6JRWK=
GR-ST M2S3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnUPXhKSzVyPUCuNFU3OjFizszN MVfTRW5ITVJ?
KARPAS-422 NGH6XWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEW2OUDPxE1? Ml7qV2FPT0WU
RPMI-8866 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PlcWlEPTB;MD6wOVcyOiEQvF2= NXq2dIZMW0GQR1XS
SCLC-21H NE\uVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES2VnBKSzVyPUCuNFU5QDRizszN M2PMZ3NCVkeHUh?=
COR-L88 M3KxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjs[ZpSUUN3ME2wMlA2QTJ5IN88US=> MUDTRW5ITVJ?
LU-139 NX\FdmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEW5PFYh|ryP NGDvcnJUSU6JRWK=
SF126 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f6VGlEPTB;MD6wOlE{OyEQvF2= MUTTRW5ITVJ?
NCI-H1882 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorzTWM2OD1yLkC2OFI1KM7:TR?= NHzTUZVUSU6JRWK=
EW-24 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[1WGlEPTB;MD6wOlQ5OyEQvF2= MVvTRW5ITVJ?
CP67-MEL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLlTWM2OD1yLkC2PFEh|ryP NH33S5RUSU6JRWK=
DG-75 NHH6bHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\ycFZJUUN3ME2wMlA3QDl7IN88US=> NGHmdGVUSU6JRWK=
LOXIMVI M4rPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nIS2lEPTB;MD6wO|AzQCEQvF2= NGr3PHBUSU6JRWK=
HH NGe0fW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC1e|NKSzVyPUCuNFcyPTdizszN MkHqV2FPT0WU
K5 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7qO|FKSzVyPUCuNFczOjZizszN M{LJbnNCVkeHUh?=
EC-GI-10 M3jW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEeyOVch|ryP M{LtWnNCVkeHUh?=
SK-N-DZ MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HEVWlEPTB;MD6wO|MxPyEQvF2= MYrTRW5ITVJ?
A3-KAW MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHQT5FKSzVyPUCuNFc{PTFizszN M4XQUnNCVkeHUh?=
MLMA M4XGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEe0OlUh|ryP MoW4V2FPT0WU
LB996-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPYcXRKSzVyPUCuNFc4ODdizszN NUTLUZR[W0GQR1XS
OS-RC-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e5W2lEPTB;MD6wO|c1QCEQvF2= MX3TRW5ITVJ?
CTB-1 M{XMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jUTWlEPTB;MD6wO|gyKM7:TR?= MXfTRW5ITVJ?
IST-MES1 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:yZWlEPTB;MD6wO|kyOiEQvF2= NYXkbZg4W0GQR1XS
LS-1034 NFW4cYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXHZpIzUUN3ME2wMlA5ODN3IN88US=> MUPTRW5ITVJ?
HT NYrwTpBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPnZXNLUUN3ME2wMlA5ODh4IN88US=> NV3kdItnW0GQR1XS
NCI-H2141 NYXZVYgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEixJO69VQ>? MoruV2FPT0WU
LB2518-MEL M1nWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXVO2o2UUN3ME2wMlA5OTRzIN88US=> MorCV2FPT0WU
GI-ME-N Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnnTWM2OD1yLkC4OFUzKM7:TR?= NVzwdmlEW0GQR1XS
TGW NGTRRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n4NWlEPTB;MD6wPFYxPyEQvF2= M3jXN3NCVkeHUh?=
SK-NEP-1 NEXXVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnqTWM2OD1yLkC4OlQyKM7:TR?= NIK3T5VUSU6JRWK=
NOMO-1 NUG5WFlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDxXYpKSzVyPUCuNFkzPzVizszN Mn7OV2FPT0WU
ES6 NX7u[Wp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHuZoxKSzVyPUCuNFk2QDlizszN NHyxO3pUSU6JRWK=
NCI-H209 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LOfmlEPTB;MD6wPVc5PiEQvF2= NHrzVpRUSU6JRWK=
GAK MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HRWWlEPTB;MD6xNFE3KM7:TR?= MYHTRW5ITVJ?
BC-1 NYnyPFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMUCzOlEh|ryP NWGwTo1yW0GQR1XS
KLE MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\oSFFPUUN3ME2wMlExPDR|IN88US=> MWjTRW5ITVJ?
EW-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPXTWM2OD1yLkGwPVgh|ryP MXjTRW5ITVJ?
NKM-1 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMUGxJO69VQ>? MUTTRW5ITVJ?
D-336MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLYNVBKSzVyPUCuNVEzPDRizszN MoDYV2FPT0WU
NB69 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\KemhCUUN3ME2wMlEyOzBzIN88US=> MmTnV2FPT0WU
D-263MG NHjvRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP4WGVKSzVyPUCuNVE4OTJizszN Moj1V2FPT0WU
KP-N-YS NWLJZYtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHYTWM2OD1yLkGyNlkyKM7:TR?= NYOzWZNEW0GQR1XS
NCI-H1155 MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMUK1OVgh|ryP MWLTRW5ITVJ?
BOKU M3HpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMUK1O|kh|ryP MYXTRW5ITVJ?
LAMA-84 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T1[2lEPTB;MD6xNlk6KM7:TR?= NGfsOoJUSU6JRWK=
Raji M3PvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHuepZKSzVyPUCuNVMyOTdizszN NIn0O3RUSU6JRWK=
LU-65 NFnOXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMUOzNFch|ryP MVHTRW5ITVJ?
NCI-H187 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXtT5RrUUN3ME2wMlE{QTJ2IN88US=> NETF[VhUSU6JRWK=
GCIY NVr2W3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF60c5ZKSzVyPUCuNVQ6ODFizszN MmD6V2FPT0WU
NCI-H2107 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMUWwPEDPxE1? MWnTRW5ITVJ?
NCI-H1522 NX\S[W1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuxOopRUUN3ME2wMlE2OjZ4IN88US=> NGPFfIJUSU6JRWK=
NB6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMUW2NlMh|ryP NHrHWZZUSU6JRWK=
EM-2 NFyxfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvLTWM2OD1yLkG1O|A3KM7:TR?= NWLKPYM6W0GQR1XS
HCC2218 M1WxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjITWM2OD1yLkG1PVgh|ryP MoLJV2FPT0WU
NCI-H748 NGfuephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\MdXR7UUN3ME2wMlE3Ozd4IN88US=> NIjLSlZUSU6JRWK=
MS-1 NHfGVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMU[1N|ch|ryP MkfPV2FPT0WU
NB5 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDKVHhKSzVyPUCuNVY2QTdizszN NVy5ZWRYW0GQR1XS
OMC-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPJO2twUUN3ME2wMlE3Pjh6IN88US=> NX3SZoJqW0GQR1XS
NCI-H345 NVPzc4NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMU[5Nlgh|ryP MojPV2FPT0WU
L-428 NWft[o1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMU[5OFUh|ryP NGjjWmNUSU6JRWK=
SCH NVH1coQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\hW5BiUUN3ME2wMlE5Pjh3IN88US=> NHLsV5NUSU6JRWK=
NCI-H1417 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMUmyNlch|ryP Mn7RV2FPT0WU
COLO-320-HSR M4fhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;LV2lEPTB;MD6xPVU{OiEQvF2= MlHXV2FPT0WU
BT-474 M3O1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLlSFdKSzVyPUCuNlA5QTJizszN NUDpemZ2W0GQR1XS
GDM-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPQTWM2OD1yLkKxPVcyKM7:TR?= MY\TRW5ITVJ?
NCI-H2196 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfmb3dNUUN3ME2wMlIzOjN3IN88US=> NY\3fWM5W0GQR1XS
KP-N-RT-BM-1 M2TjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe3[3pOUUN3ME2wMlIzOzR7IN88US=> NV\zRYE1W0GQR1XS
KNS-81-FD MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfDOXVGUUN3ME2wMlIzQTV6IN88US=> MWDTRW5ITVJ?
COLO-668 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMkO2O|Uh|ryP MlP0V2FPT0WU
C2BBe1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:wdmlEPTB;MD6yOlc1PyEQvF2= NHi0SWxUSU6JRWK=
Ramos-2G6-4C10 NVH5b3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMk[5OVQh|ryP MU\TRW5ITVJ?
CAS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7KTJNKSzVyPUCuNlcxQTZizszN MXPTRW5ITVJ?
GOTO MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:xdINNUUN3ME2wMlI4QDl2IN88US=> MU\TRW5ITVJ?
LP-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMkiwOVch|ryP MWXTRW5ITVJ?
NCI-SNU-1 NGrzU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;DemlEPTB;MD6yPVQzOiEQvF2= NVn1fotzW0GQR1XS
EB-3 NEXkUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXaXmdqUUN3ME2wMlI6QTd7IN88US=> Ml\RV2FPT0WU
MHH-NB-11 M4HCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXpTWM2OD1yLkOwOFAzKM7:TR?= M1rYb3NCVkeHUh?=
SK-N-FI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fxT2lEPTB;MD6zNVY6OiEQvF2= MUPTRW5ITVJ?
HCC2157 Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrsPZBKSzVyPUCuN|M6OTNizszN MoHtV2FPT0WU
SIMA NFr3ZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLsTWM2OD1yLkO0OVgyKM7:TR?= MkjpV2FPT0WU
MDA-MB-134-VI NHzNboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHEV4pOUUN3ME2wMlM3QTJ6IN88US=> MonvV2FPT0WU
NCI-H1694 NEC3U3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDlelJKSzVyPUCuN|ch|ryP MUXTRW5ITVJ?
EHEB NYjQd|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSxTWM2OD1yLkO5NFg2KM7:TR?= NHrYU45USU6JRWK=
U-266 NXvXZXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HR[WlEPTB;MD6zPVg1PiEQvF2= NUf0WmdzW0GQR1XS
LC-1F NV;mZ4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDXNZNKSzVyPUCuOFM4PjVizszN MYjTRW5ITVJ?
SHP-77 M{PFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvuUFdKSzVyPUCuOFc5PTVizszN NEL2TlRUSU6JRWK=
LS-513 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHIVlVxUUN3ME2wMlQ6OzB5IN88US=> NEi2NY1USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03694002 Recruiting Locally Advanced Thymic Carcinoma|Metastatic Thymic Carcinoma|Recurrent Thymic Carcinoma|Unresectable Thymic Carcinoma Southwest Oncology Group|National Cancer Institute (NCI) August 9 2018 Phase 2
NCT03275818 Recruiting Tumor Desmoplastic Small Round Cell Adult|Tumor Desmoplastic Small Round Cell Childhood|Sarcoma Ewing|Sarcoma|Desmoid Grupo Espanol de Investigacion en Sarcomas May 9 2017 Phase 2
NCT03057600 Active not recruiting Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer Calithera Biosciences Inc May 9 2017 Phase 2
NCT02775435 Active not recruiting Non-small Cell Lung Cancer Merck Sharp & Dohme Corp. June 9 2016 Phase 3
NCT02181634 Completed Cholangiocarcinoma PrECOG LLC.|Celgene Corporation December 9 2014 Phase 2
NCT02415023 Completed Gastric Cancer Hutchison Medipharma Limited November 9 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID